In 2025, the Russian healthcare system received 1.66 million packages of finished medicinal products based on botulinum toxins. This is an absolute historical record; a year earlier, Russian and foreign manufacturers supplied 1.54 million packages, thus we are recording a growth rate of 7.7%. The total volume of supply in equivalent units of activity (U)* reached 157 million last year (+5.9% compared to 2024 figures). Despite this apparent success, it should be noted that this growth rate for the analyzed category is one of the worst in the last 7 years. Lower dynamics were only recorded in 2023 (+0.7% in packages), but that was associated with the cessation of official supplies to the Russian market of two products simultaneously: Botox from Allergan and Botulax from Hugel. The golden era for the category was the period from 2019 to 2021, when the annual supply dynamics averaged around 85%. The years 2022 and 2024 were also characterized by high growth rates, with the total volume of shipped packages increasing by 41% and 38%, respectively.

The assortment of botulinum toxins legally shipped to the Russian market did not change in 2025. Moreover, according to the database "Monitoring of the Release of Medicinal Products into Free Circulation in Russia" from the analytical company RNC Pharma, starting from January 2026, supplies of another "new" botulinum toxin commenced – the drug Lantox from Binnopharm Group. This drug is interesting for two reasons. First, it was already present on the market some time ago; its supplies ceased in 2018, but at that time it did not play a significant role in the market. The second point is that this is currently one of the few products on the Russian pharmaceutical market whose full production cycle is carried out in China.

The absolute leader in terms of the number of packages supplied to the market in 2025 is the Russian drug Relatox from Nacimbio. Last year, the company shipped 630,300 packs, accounting for 37.9% of the total volume. However, the absolute leader in equivalent units of activity is still Dysport from Ipsen. In total, in 2025, the manufacturer released 52.6 million units of the drug onto the Russian market, corresponding to a 33.5% market share. The gap from Relatox is relatively small, only 0.5%, as the Russian company supplied 51.9 million equivalent units over the year. It is noteworthy that the dynamics for the products are in opposite directions. When calculated in units of activity, Dysport supplies decreased by 9% compared to 2024, while Relatox supplies grew by 13%. The absolute record holder in terms of growth dynamics was Xeomin from Merz Pharma; the release of the drug into circulation increased by 68% in equivalent units over the year. Among the outsiders for now are Myotox from the Russian company Innofarm (-22% in units) and the 2023 new product – Novacutan-BTA from the Institut Krasoty Fizi (-35%).

As of January 2026, the Russian market has already received 252,400 packages (25.2 million equivalent units) of botulinum toxin drugs. This is roughly double the average monthly volume of the previous year, but drawing conclusions about suppliers' future activity in the new year based on data from just one month is, of course, premature.

Figure. Supply Dynamics of Domestic and Imported Botulinum Toxin Drugs to the Russian Market in 2016–2025, in packages and equivalent units of activity (U)

*Equivalent units of activity take into account that the effective therapeutic dose of the drug Dysport (Ipsen) for aesthetic indications correlates with other botulinum toxin drugs at a ratio of 3 to 1.